Landmark trial ONTARGET® proves telmisartan is as protective as ramipril and better tolerated in a broad high-risk cardiovascula
  • MultiVu
  • 구독 36 명
0 담기
47 조회 ㆍ 10년 전 업로드
#MICARDIS #ARB #cardiovascular

Results of 25,620 patient study ONTARGET® (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) presented today at the 57th Annual Scientific Session of the American College ...